Substance / Medication

Mequitazine

Overview

Active Ingredient
mequitazine
RxNorm CUI
29528

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Evaluation of Pharmacological Treatments for Acute Urticaria: A Systematic Review and Meta-Analysis.
Jamjanya Sirinda, Danpanichkul Pojsakorn, Ongsupankul Sorawit et al. · J Allergy Clin Immunol Pract · 2024
PMID: 38280453Meta-Analysis
Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Chu Xiajing, Wang Jason, Ologundudu Leonardo et al. · J Allergy Clin Immunol Pract · 2024
PMID: 38642709Meta-Analysis
Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: Systematic review and meta-analysis of randomized clinical trials.
Rayner Daniel G, Liu Ming, Chu Alexandro W L et al. · J Allergy Clin Immunol · 2024
PMID: 38852861Meta-Analysis
Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.
Ansotegui Ignacio J, Bousquet Jean, Canonica Giorgio Walter et al. · Curr Med Res Opin · 2024
PMID: 39028636Meta-Analysis
On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol.
van der Sluiszen N N J J M, Vermeeren A, Jongen S et al. · Psychopharmacology (Berl) · 2016
PMID: 27488192RCTFull text (PMC)
Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance.
Theunissen Eef L, Vermeeren Annemiek, Ramaekers Johannes G · Br J Clin Pharmacol · 2006
PMID: 16390354RCTFull text (PMC)
[Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone].
Richard C, Bibas P, Lablache-Combier M et al. · J Fr Ophtalmol · 2005
PMID: 15883488Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mequitazine (substance)
SNOMED CT
414674005
UMLS CUI
C0065972
RxNorm CUI
29528

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.